Evaxion A/S (EVAX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Evaxion A/S
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 7.5M | 0.00 | 0.00 | 0.00 |
| Operating Income | 3.0M | (4.1M) | (3.8M) | (3.8M) |
| Net Income | 4.6M | (5.9M) | (3.6M) | (3.7M) |
| Diluted EPS | $0.50 | $-1.00 | $-0.50 | $-0.50 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 73K | 3.3M | 7.5M |
| Operating Income | (25.3M) | (22.2M) | (14.7M) | (9.2M) |
| Net Income | (23.2M) | (22.1M) | (10.6M) | (7.7M) |
| Diluted EPS | $-49.00 | $-40.50 | $-10.00 | $-1.00 |